サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1269443

放射性医薬品セラノスティクス市場- 世界の産業分析、規模、シェア、成長、動向、予測、2023-2031年

Radiopharmaceutical Theranostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 226 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
放射性医薬品セラノスティクス市場- 世界の産業分析、規模、シェア、成長、動向、予測、2023-2031年
出版日: 2023年03月20日
発行: Transparency Market Research
ページ情報: 英文 226 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

放射性医薬品セラノスティクス市場- 調査範囲：

TMRの調査レポート「放射性医薬品セラノスティクスの世界市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向と機会も調査しています。本レポートでは、2023年を基準年、2031年を予測年として考え、2017年から2031年までの放射性医薬品セラノスティクスの世界市場の収益を提供します。また、2023年から2031年までの放射性医薬品セラノスティクスの世界市場のCAGRを掲載しています。

本レポートは、広範な調査を経て作成されました。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施し、調査作業の大部分を行っています。2次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、放射性医薬品セラノスティクス市場を理解しました。

本レポートは、世界の放射性医薬品セラノスティクス市場の競合情勢を掘り下げています。世界の放射性医薬品セラノスティクス市場で活動する主要企業が特定され、それぞれの企業が様々な属性でプロファイリングされています。企業概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の放射性医薬品セラノスティクス市場におけるプレイヤーの属性です。

目次

第1章 序文

  • 市場の定義とスコープ
  • 市場セグメンテーション
  • 主な調査目的
  • 調査ハイライト

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場の概要

  • イントロダクション
    • 定義
    • 業界の進化と発展
  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • 世界市場の分析と予測、2017-2031年
    • 市場収益予測

第5章 主な洞察

  • 法規制のシナリオ
  • 主要な流通戦略
  • 価格設定に関する分析
  • 放射性トレーサーに関する特許
  • 放射性トレーサーの技術的進歩
  • 放射性トレーサーの種類- 概要
  • COVID-19パンデミックによる産業への影響

第6章 世界市場分析・予測：放射性同位元素別

  • イントロダクションと定義
  • 主な調査結果/発展状況
  • 市場価値予測：放射性同位元素別、2017-2031年
    • テクネチウム-99
    • ガリウム-68
    • ヨウ素-131
    • ラジウム-223
    • フッ素-18
    • イットリウム-90
    • ルテチウム-177
    • 銅-67＆64
    • サマリウム-153
    • その他
  • 市場魅力分析：放射性同位元素別

第7章 世界市場分析・予測：アプリケーション別

  • イントロダクション＆定義
  • 主な調査結果/発展状況
  • 市場価値予測：アプリケーション別、2017-2031年
    • オンコロジー
    • 心臓病学
    • その他
  • 市場魅力分析：アプリケーション別

第8章 世界市場分析・予測：ソース別

  • イントロダクション＆定義
  • 主な調査結果/発展状況
  • 市場価値予測：ソース別、2017-2031年
    • 原子炉
    • サイクロトロン
  • 市場魅力分析：ソース別

第9章 世界市場分析・予測：アプローチ別

  • イントロダクションと定義
  • 主な調査結果/発展状況
  • 市場価値予測：アプローチ別、2017年～2031年
    • 標的治療薬（Rx）
    • コンパニオン診断薬（DX）
  • 市場魅力分析：アプローチ別

第10章 世界市場分析・予測：放射性トレーサータイプ別

  • イントロダクションと定義
  • 主な調査結果/発展状況
  • 市場価値予測：放射性トレーサータイプ別、2017-2031年
    • ペプチド性
    • 非ペプチド性
  • 市場魅力分析：ラジオトレーサータイプ別

第11章 世界市場分析・予測：エンドユーザー別

  • イントロダクション＆定義
  • 主な調査結果/発展状況
  • 市場規模予測：エンドユーザー別、2017年～2031年
    • 病院
    • 学術・研究機関
    • その他
  • 市場魅力分析：エンドユーザー別

第12章 世界市場分析・予測：地域別

  • 主な調査結果
  • 市場価値予測：地域別、2017-2031年
    • 米国
    • 欧州
    • 世界のその他の地域
  • 市場魅力分析：地域別

第13章 米国市場分析・予測

  • イントロダクション
    • 主な調査結果
  • 市場規模予測：放射性同位元素別、2017年～2031年
    • テクネチウム-99
    • ガリウム-68
    • ヨウ素-131
    • ラジウム-223
    • フッ素-18
    • イットリウム-90
    • ルテチウム-177
    • 銅-67＆64
    • サマリウム-153
    • その他
  • 市場価値予測：アプリケーション別、2017-2031年
    • オンコロジー
    • 心臓病学
    • その他
  • 市場価値予測：供給源別、2017-2031年
    • 原子炉
    • サイクロトロン
  • 市場価値予測：アプローチ別、2017-2031年
    • 標的治療薬（Rx）
    • コンパニオン診断薬（DX）
  • 市場価値予測：放射性トレーサータイプ別、2017-2031年
    • ペプチド性
    • 非ペプチド性
  • 市場価値予測：エンドユーザー別、2017-2031年
    • 病院
    • 学術・研究機関
    • その他
  • 市場魅力分析
    • 放射性同位元素別
    • 用途別
    • 供給源別
    • アプローチ別
    • 放射性トレーサータイプ別
    • エンドユーザー別

第14章 欧州市場の分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：放射性同位元素別、2017-2031年
    • テクネチウム-99
    • ガリウム-68
    • ヨウ素-131
    • ラジウム-223
    • フッ素-18
    • イットリウム-90
    • ルテチウム-177
    • 銅-67＆64
    • サマリウム-153
    • その他
  • 市場価値予測：アプリケーション別、2017-2031年
    • オンコロジー
    • 心臓病学
    • その他
  • 市場価値予測：供給源別、2017-2031年
    • 原子炉
    • サイクロトロン
  • 市場価値予測：アプローチ別、2017-2031年
    • 標的治療薬（Rx）
    • コンパニオン診断薬（DX）
  • 市場価値予測：放射性トレーサータイプ別、2017-2031年
    • ペプチド性
    • 非ペプチド性
  • 市場価値予測：エンドユーザー別、2017-2031年
    • 病院
    • 学術・研究機関
    • その他
  • 市場価値予測：国・小地域別、2017-2031年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 市場魅力分析
    • 放射性同位元素別
    • アプリケーション別
    • ソース別
    • アプローチ別
    • 放射性トレーサータイプ別
    • エンドユーザー別
    • 国別／サブリージョン別

第15章 世界のその他の地域の市場分析と予測

  • イントロダクション
    • 主要な調査結果
  • 市場価値予測：放射性同位元素別、2017年～2031年
    • テクネチウム-99
    • ガリウム-68
    • ヨウ素-131
    • ラジウム-223
    • フッ素-18
    • イットリウム-90
    • ルテチウム-177
    • 銅-67＆64
    • サマリウム-153
    • その他
  • 市場価値予測：アプリケーション別、2017-2031年
    • オンコロジー
    • 心臓病学
    • その他
  • 市場価値予測：供給源別、2017-2031年
    • 原子炉
    • サイクロトロン
  • 市場価値予測：アプローチ別、2017-2031年
    • 標的治療薬（Rx）
    • コンパニオン診断薬（DX）
  • 市場価値予測：放射性トレーサータイプ別、2017-2031年
    • ペプチド性
    • 非ペプチド性
  • 市場価値予測：エンドユーザー別、2017-2031年
    • 病院
    • 学術・研究機関
    • その他
  • 市場魅力分析
    • 放射性同位元素別
    • 用途別
    • 供給源別
    • アプローチ別
    • 放射性トレーサータイプ別
    • エンドユーザー別

第16章 競合情勢

  • 市場競争マトリックス（企業階層別、企業規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Advanced Accelerator Applications（Novartis AG）
    • Aurobindo Pharma
    • Bayer AG
    • Blue Earth Diagnostics（Bracco）
    • Cardinal Health
    • Clarity Pharmaceuticals
    • GE Healthcare
    • Jubliant Radiopharma
    • Lantheus Medical Imaging
    • Navidea Biopharmaceuticals, Inc.
    • SOFIE
    • Telix Pharmaceuticals
図表

List of Tables

  • Table 01: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017-2031
  • Table 02: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 03: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017-2031
  • Table 04: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017-2031
  • Table 05: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017-2031
  • Table 06: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 07: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Region, 2017-2031
  • Table 08: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017-2031
  • Table 09: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 10: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017-2031
  • Table 11: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017-2031
  • Table 12: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017-2031
  • Table 13: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 14: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 15: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017-2031
  • Table 16: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 17: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017-2031
  • Table 18: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017-2031
  • Table 19: EU Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017-2031
  • Table 20: EU Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017-2031
  • Table 22: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 23: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017-2031
  • Table 24: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017-2031
  • Table 25: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017-2031
  • Table 26: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Radiopharmaceutical Theranostics Market Value Share, by Radioisotope, 2022
  • Figure 03: Global Radiopharmaceutical Theranostics Market Value Share, by Application, 2022
  • Figure 04: Global Radiopharmaceutical Theranostics Market Value Share, by Source, 2022
  • Figure 05: Global Radiopharmaceutical Theranostics Market Value Share, by Approach, 2022
  • Figure 06: Global Radiopharmaceutical Theranostics Market Value Share, by End-user, 2022
  • Figure 07: Global Radiopharmaceutical Theranostics Market Value Share, by Radiotracer Type, 2022
  • Figure 08: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2022 and 2031
  • Figure 09: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radioisotope, 2023-2031
  • Figure 10: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Technetium-99, 2017-2031
  • Figure 11: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Gallium-68, 2017-2031
  • Figure 12: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Iodine-131, 2017-2031
  • Figure 13: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Radium-223, 2017-2031
  • Figure 14: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Fluorine-18, 2017-2031
  • Figure 15: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Yttrium-90, 2017-2031
  • Figure 16: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Lutetium-177, 2017-2031
  • Figure 17: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Copper-67 & 64, 2017-2031
  • Figure 18: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Samarium-153, 2017-2031
  • Figure 19: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 20: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 21: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Application, 2023-2031
  • Figure 22: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Oncology, 2017-2031
  • Figure 23: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Cardiology, 2017-2031
  • Figure 24: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 25: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2022 and 2031
  • Figure 26: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Source, 2023-2031
  • Figure 27: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Nuclear Reactors, 2017-2031
  • Figure 28: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Cyclotrons, 2017-2031
  • Figure 29: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2022 and 2031
  • Figure 30: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Approach, 2023-2031
  • Figure 31: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Targeted Therapeutic (Rx), 2017-2031
  • Figure 32: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Companion Diagnostic (DX), 2017-2031
  • Figure 33: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Radiotracer Type, 2022 and 2031
  • Figure 34: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radiotracer Type, 2023-2031
  • Figure 35: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Peptidic, 2017-2031
  • Figure 36: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Non-peptidic, 2017-2031
  • Figure 37: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user 2022 and 2031
  • Figure 38: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, End-user, 2023-2031
  • Figure 39: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Hospitals, 2017-2031
  • Figure 40: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Academic & Research Institutes, 2017-2031
  • Figure 41: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 42: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Country/Region, 2022 and 2031
  • Figure 43: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Country/Region, 2023-2031
  • Figure 44: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 45: U.S. Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2022 and 2031
  • Figure 46: U.S. Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radioisotope, 2023-2031
  • Figure 47: U.S. Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 48: U.S. Radiopharmaceutical Theranostics Market Attractiveness Analysis, Application, 2023-2031
  • Figure 49: U.S. Radiopharmaceutical Theranostics Market Value Share Analysis, by Source 2022, and 2031
  • Figure 50: U.S. Radiopharmaceutical Theranostics Market Attractiveness Analysis, Source, 2023-2031
  • Figure 51: U.S. Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2022 and 2031
  • Figure 52: U.S. Radiopharmaceutical Theranostics Market Attractiveness Analysis, Approach, 2023-2031
  • Figure 53: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Radiotracer Type, 2022 and 2031
  • Figure 54: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radiotracer Type, 2023-2031
  • Figure 55: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 56: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, End-user, 2023-2031
  • Figure 57: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 58: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 59: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 60: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2022 and 2031
  • Figure 61: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radioisotope, 2023-2031
  • Figure 62: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 63: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, Application, 2023-2031
  • Figure 64: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2022 and 2031
  • Figure 65: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, Source, 2023-2031
  • Figure 66: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2022 and 2031
  • Figure 67: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, Approach, 2023-2031
  • Figure 68: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Radiotracer Type, 2022 and 2031
  • Figure 69: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radiotracer Type, 2023-2031
  • Figure 70: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 71: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, End-user, 2023-2031
  • Figure 72: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 73: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2022 and 2031
  • Figure 74: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radioisotope, 2023-2031
  • Figure 75: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 76: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, Application, 2023-2031
  • Figure 77: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2022 and 2031
  • Figure 78: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, Source, 2023-2031
  • Figure 79: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2022 and 2031
  • Figure 80: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, Approach, 2023-2031
  • Figure 81: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by Radiotracer Type, 2022 and 2031
  • Figure 82: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radiotracer Type, 2023-2031
  • Figure 83: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user 2022 and 2031
  • Figure 84: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, End-user, 2023-2031
目次
Product Code: TMRGL82604

Radiopharmaceutical Theranostics Market - Scope of Report:

TMR's report on the global radiopharmaceutical theranostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global radiopharmaceutical theranostics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global radiopharmaceutical theranostics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the radiopharmaceutical theranostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global radiopharmaceutical theranostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global radiopharmaceutical theranostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global radiopharmaceutical theranostics market.

The report delves into the competitive landscape of the global radiopharmaceutical theranostics market. Key players operating in the global radiopharmaceutical theranostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global radiopharmaceutical theranostics market profiled in this report.

Key Questions Answered in Global Radiopharmaceutical Theranostics Market Report:

  • What is the sales/revenue generated by radiopharmaceutical theranostics across all regions during the forecast period?
  • What are the opportunities in the global radiopharmaceutical theranostics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Radiopharmaceutical Theranostics Market - Research Objectives and Research Approach:

The comprehensive report on the global radiopharmaceutical theranostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global radiopharmaceutical theranostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global radiopharmaceutical theranostics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Radiopharmaceutical Theranostics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Regulatory Scenario
  • 5.2. Key Distribution Strategies
  • 5.3. Pricing Analysis
  • 5.4. Patents on Radiotracers
  • 5.5. Technological Advancements in Radiopharmaceutical Theranostics
  • 5.6. Radiotracer Type - Overview
  • 5.7. COVID-19 Pandemic Impact on Industry

6. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radioisotope

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Radioisotope, 2017-2031
    • 6.3.1. Technetium-99
    • 6.3.2. Gallium-68
    • 6.3.3. Iodine-131
    • 6.3.4. Radium-223
    • 6.3.5. Fluorine-18
    • 6.3.6. Yttrium-90
    • 6.3.7. Lutetium-177
    • 6.3.8. Copper-67 & 64
    • 6.3.9. Samarium-153
    • 6.3.10. Others
  • 6.4. Market Attractiveness Analysis, by Radioisotope

7. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Application, 2017-2031
    • 7.3.1. Oncology
    • 7.3.2. Cardiology
    • 7.3.3. Others
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Source

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Source, 2017-2031
    • 8.3.1. Nuclear Reactors
    • 8.3.2. Cyclotrons
  • 8.4. Market Attractiveness Analysis, by Source

9. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Approach

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Approach, 2017-2031
    • 9.3.1. Targeted Therapeutic (Rx)
    • 9.3.2. Companion Diagnostic (DX)
  • 9.4. Market Attractiveness Analysis, by Approach

10. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radiotracer Type

  • 10.1. Introduction & Definition
  • 10.2. Key Findings/Developments
  • 10.3. Market Value Forecast, by Radiotracer Type, 2017-2031
    • 10.3.1. Peptidic
    • 10.3.2. Non-peptidic
  • 10.4. Market Attractiveness Analysis, by Radiotracer Type

11. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by End-user

  • 11.1. Introduction & Definition
  • 11.2. Key Findings/Developments
  • 11.3. Market Value Forecast, by End-user, 2017-2031
    • 11.3.1. Hospitals
    • 11.3.2. Academic & Research Institutes
    • 11.3.3. Others
  • 11.4. Market Attractiveness Analysis, by End-user

12. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Region

  • 12.1. Key Findings
  • 12.2. Market Value Forecast, by Region, 2017-2031
    • 12.2.1. U.S.
    • 12.2.2. Europe
    • 12.2.3. Rest of the World
  • 12.3. Market Attractiveness Analysis, by Region

13. U.S. Radiopharmaceutical Theranostics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Radioisotope, 2017-2031
    • 13.2.1. Technetium-99
    • 13.2.2. Gallium-68
    • 13.2.3. Iodine-131
    • 13.2.4. Radium-223
    • 13.2.5. Fluorine-18
    • 13.2.6. Yttrium-90
    • 13.2.7. Lutetium-177
    • 13.2.8. Copper-67 & 64
    • 13.2.9. Samarium-153
    • 13.2.10. Others
  • 13.3. Market Value Forecast, by Application, 2017-2031
    • 13.3.1. Oncology
    • 13.3.2. Cardiology
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by Source, 2017-2031
    • 13.4.1. Nuclear Reactors
    • 13.4.2. Cyclotrons
  • 13.5. Market Value Forecast, by Approach, 2017-2031
    • 13.5.1. Targeted Therapeutic (Rx)
    • 13.5.2. Companion Diagnostic (DX)
  • 13.6. Market Value Forecast, by Radiotracer Type, 2017-2031
    • 13.6.1. Peptidic
    • 13.6.2. Non-peptidic
  • 13.7. Market Value Forecast, by End-user, 2017-2031
    • 13.7.1. Hospitals
    • 13.7.2. Academic & Research Institutes
    • 13.7.3. Others
  • 13.8. Market Attractiveness Analysis
    • 13.8.1. By Radioisotope
    • 13.8.2. By Application
    • 13.8.3. By Source
    • 13.8.4. By Approach
    • 13.8.5. By Radiotracer Type
    • 13.8.6. By End-user

14. Europe Radiopharmaceutical Theranostics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Radioisotope, 2017-2031
    • 14.2.1. Technetium-99
    • 14.2.2. Gallium-68
    • 14.2.3. Iodine-131
    • 14.2.4. Radium-223
    • 14.2.5. Fluorine-18
    • 14.2.6. Yttrium-90
    • 14.2.7. Lutetium-177
    • 14.2.8. Copper-67 & 64
    • 14.2.9. Samarium-153
    • 14.2.10. Others
  • 14.3. Market Value Forecast, by Application, 2017-2031
    • 14.3.1. Oncology
    • 14.3.2. Cardiology
    • 14.3.3. Others
  • 14.4. Market Value Forecast, by Source, 2017-2031
    • 14.4.1. Nuclear Reactors
    • 14.4.2. Cyclotrons
  • 14.5. Market Value Forecast, by Approach, 2017-2031
    • 14.5.1. Targeted Therapeutic (Rx)
    • 14.5.2. Companion Diagnostic (DX)
  • 14.6. Market Value Forecast, by Radiotracer Type, 2017-2031
    • 14.6.1. Peptidic
    • 14.6.2. Non-peptidic
  • 14.7. Market Value Forecast, by End-user, 2017-2031
    • 14.7.1. Hospitals
    • 14.7.2. Academic & Research Institutes
    • 14.7.3. Others
  • 14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.8.1. Germany
    • 14.8.2. U.K.
    • 14.8.3. France
    • 14.8.4. Italy
    • 14.8.5. Spain
    • 14.8.6. Rest of Europe
  • 14.9. Market Attractiveness Analysis
    • 14.9.1. By Radioisotope
    • 14.9.2. By Application
    • 14.9.3. By Source
    • 14.9.4. By Approach
    • 14.9.5. By Radiotracer Type
    • 14.9.6. By End-user
    • 14.9.7. By Country/Sub-region

15. Rest of the World Radiopharmaceutical Theranostics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Radioisotope, 2017-2031
    • 15.2.1. Technetium-99
    • 15.2.2. Gallium-68
    • 15.2.3. Iodine-131
    • 15.2.4. Radium-223
    • 15.2.5. Fluorine-18
    • 15.2.6. Yttrium-90
    • 15.2.7. Lutetium-177
    • 15.2.8. Copper-67 & 64
    • 15.2.9. Samarium-153
    • 15.2.10. Others
  • 15.3. Market Value Forecast, by Application, 2017-2031
    • 15.3.1. Oncology
    • 15.3.2. Cardiology
    • 15.3.3. Others
  • 15.4. Market Value Forecast, by Source, 2017-2031
    • 15.4.1. Nuclear Reactors
    • 15.4.2. Cyclotrons
  • 15.5. Market Value Forecast, by Approach, 2017-2031
    • 15.5.1. Targeted Therapeutic (Rx)
    • 15.5.2. Companion Diagnostic (DX)
  • 15.6. Market Value Forecast, by Radiotracer Type, 2017-2031
    • 15.6.1. Peptidic
    • 15.6.2. Non-peptidic
  • 15.7. Market Value Forecast, by End-user, 2017-2031
    • 15.7.1. Hospitals
    • 15.7.2. Academic & Research Institutes
    • 15.7.3. Others
  • 15.8. Market Attractiveness Analysis
    • 15.8.1. By Radioisotope
    • 15.8.2. By Application
    • 15.8.3. By Source
    • 15.8.4. By Approach
    • 15.8.5. By Radiotracer Type
    • 15.8.6. By End-user

16. Competition Landscape

  • 16.1. Market Player Competition Matrix (by tier and size of companies)
  • 16.2. Market Share Analysis, by Company (2022)
  • 16.3. Company Profiles
    • 16.3.1. Advanced Accelerator Applications (Novartis AG)
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Aurobindo Pharma
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Bayer AG
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Blue Earth Diagnostics (Bracco)
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Cardinal Health
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Clarity Pharmaceuticals
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. GE Healthcare
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Jubliant Radiopharma
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Lantheus Medical Imaging
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Navidea Biopharmaceuticals, Inc.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. SOFIE
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview
    • 16.3.12. Telix Pharmaceuticals
      • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.12.2. Product Portfolio
      • 16.3.12.3. Financial Overview
      • 16.3.12.4. SWOT Analysis
      • 16.3.12.5. Strategic Overview